1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer

 
• By Jessica Merrill

Merck’s Keytruda improved progression-free survival and overall survival in previously untreated non-small cell lung cancer patients in the highly-anticipated KEYNOTE-024 trial, all but guaranteeing a rapid FDA approval in the indication.

Positive progression-free survival and overall survival data from Merck & Co. Inc.’s high profile KEYNOTE-024 trial testing Keytruda (pembrolizumab) in patients with previously untreated advanced non-small cell lung cancer (NSCLC) positions Keytruda to beat Bristol-Myers Squibb Co.’s Opdivo (nivolumab) to a first-line lung cancer indication.

The winner long-term in the high stakes market remains very much up in the air, however, as the details of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Who Does What? EU RADIAL Study Exposes Oversight Challenges In Decentralized Trials

 
• By Vibha Sharma

Decentralizing clinical research demands rethinking accountability and logistics to prevent gaps that could compromise safety and trial integrity.

France To Offer 14-Day Clinical Trial Reviews To Attract Research

 
• By Francesca Bruce

France is set to pilot a new fast-track process that could more than halve the timeline for authorizing certain clinical trial applications.

Europe’s Trials@Home Findings Show Remote Recruitment Is Complicated

 
• By Vibha Sharma

Europe’s RADIAL study comparing fully decentralized, hybrid and conventional trial approaches reveals why online recruitment is not simple.

UK Tests Standardized Site Selection Process For Streamlining Clinical Trial Setup

 
• By Vibha Sharma

Sponsors and CROs planning commercial trials in the UK can now use a standardized template to confirm NHS site selection and start study setup activities in parallel with formal contracting and regulatory approvals.

More from R&D

UK Tests Standardized Site Selection Process For Streamlining Clinical Trial Setup

 
• By Vibha Sharma

Sponsors and CROs planning commercial trials in the UK can now use a standardized template to confirm NHS site selection and start study setup activities in parallel with formal contracting and regulatory approvals.

Getting Comfortable With The Black Box: Explainable AI Techniques Build Trust

 
• By Bridget Silverman

A subfield of AI aims to explain why complex models make predictions, which will increase their interpretability and auditing ability, AI researcher Su-In Lee said during a National Academies of Sciences workshop.

Pharma Needs Incentives To Optimize Cancer Drugs, EMA Oncology Chair Says

 
• By Eliza Slawther

Incentives are “probably the only solution” to encouraging companies to optimize cancer drugs, but this will require funding and systemic changes, the chair of the European Medicines Agency’s oncology working party says.